Effects of Fish Oil on Post Ablation Arrhythmias

University of Michigan

Status and phase: Terminated; Phase 4

Conditions: Atrial Fibrillation

Treatments: Other: placebo; Drug: LOVAZA; Drug: LOVAZA Omega 3-acid ethyl esters

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT00791089

LVZ111900

Details and patient eligibility

About

To determine if peri-operative treatment with omega-3 fatty acids is associated with a decrease in the incidence of early recurrences of atrial arrhythmias (within 30 days) and an improvement in probability of long-term maintenance of sinus rhythm after radiofrequency catheter ablation for Atrial Fibrillation.

Full description

AF is the most prevalent arrhythmia, affecting >2 million Americans. Antiarrhythmic drug therapy often is ineffective to eliminate recurrent episodes of AF. In recent years radiofrequency catheter ablation has emerged as a highly effective treatment strategy in patients with paroxysmal and chronic AF.6, 7 However, AF may recur within days to weeks after a successful ablation procedure in up to 50% of the patients, probably because of an inflammatory response to thermal injury caused by radiofrequency energy application. These early recurrences of AF after ablation do not necessarily predict long-term clinical outcome and 30-50% of patients who develop early recurrences ultimately remain in sinus rhythm without the need for additional ablation.8 However, early recurrences of AF may be associated with significant morbidity due to troubling symptoms of rapid ventricular rates, multiple hospital visits and cardioversions, need for antiarrhythmic drug therapy and prolongation in duration of anticoagulant therapy. It is also possible that if early recurrences of AF after ablation can be avoided, the probability of remaining in sinus rhythm during long-term follow-up may be higher, as maintenance of sinus rhythm early-on may facilitate reverse left atrial remodeling. A similar phenomenon may occur in post-operative AF, that develops in ~30% of patients who undergo cardiac surgery. Post-operative AF is often transient and usually resolves within 3 months after the surgery. Perioperative treatment with omega-3 fatty acids has been reported to decrease the incidence of postoperative AF after coronary artery by-pass surgery.4 Because the pathogenetic factors that play a role in postoperative AF and early recurrences of AF after radiofrequency catheter ablation may be similar, it is plausible that treatment with omega-3 fatty acids before and after ablation will be associated with a reduction in the incidence of early recurrences of AF.

Enrollment: 12 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age > 18 years and < 70 years old
• Left atrial size <55 mm

Exclusion criteria

• Inability or unwillingness to provide informed consent
• Current therapy with omega-3 fatty acids
• Current therapy with a statin
• Active liver disease
• Significant comorbidity such as end-stage renal disease or cirrhosis
• Valvular prosthesis

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

12 participants in 2 patient groups, including a placebo group

Fish Oil, Ablation, Sinus Rhythm

Experimental group

Description:

Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.

Treatment:

Drug: LOVAZA

Drug: LOVAZA Omega 3-acid ethyl esters

placebo, Ablation, sinus rhythm

Placebo Comparator group

Description:

Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.

Treatment:

Other: placebo